Our top pick for
XOMA Corporation is a biotechnology business based in the US. XOMA Corporation shares (XOMA) are listed on the NASDAQ and all prices are listed in US Dollars. XOMA Corporation employs 10 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$15.48 - $46.32|
|50-day moving average||$37.79|
|200-day moving average||$34.93|
|Wall St. target price||$48.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.78|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing XOMA Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of XOMA Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
XOMA Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 47x. In other words, XOMA Corporation shares trade at around 47x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
XOMA Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $12.4 million.
The EBITDA is a measure of a XOMA Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$29.4 million|
|Operating margin TTM||42.25%|
|Gross profit TTM||$29.2 million|
|Return on assets TTM||7.02%|
|Return on equity TTM||20.39%|
|Market capitalisation||$423.2 million|
TTM: trailing 12 months
There are currently 419,161 XOMA Corporation shares held short by investors – that's known as XOMA Corporation's "short interest". This figure is 27.4% up from 328,909 last month.
There are a few different ways that this level of interest in shorting XOMA Corporation shares can be evaluated.
XOMA Corporation's "short interest ratio" (SIR) is the quantity of XOMA Corporation shares currently shorted divided by the average quantity of XOMA Corporation shares traded daily (recently around 97028.009259259). XOMA Corporation's SIR currently stands at 4.32. In other words for every 100,000 XOMA Corporation shares traded daily on the market, roughly 4320 shares are currently held short.
However XOMA Corporation's short interest can also be evaluated against the total number of XOMA Corporation shares, or, against the total number of tradable XOMA Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case XOMA Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 XOMA Corporation shares in existence, roughly 40 shares are currently held short) or 0.0598% of the tradable shares (for every 100,000 tradable XOMA Corporation shares, roughly 60 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against XOMA Corporation.
Find out more about how you can short XOMA Corporation stock.
We're not expecting XOMA Corporation to pay a dividend over the next 12 months.
XOMA Corporation's shares were split on a 1:20 basis on 17 October 2016. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your XOMA Corporation shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for XOMA Corporation shares which in turn could have impacted XOMA Corporation's share price.
Over the last 12 months, XOMA Corporation's shares have ranged in value from as little as $15.48 up to $46.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while XOMA Corporation's is 0.9779. This would suggest that XOMA Corporation's shares are less volatile than average (for this exchange).
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and X213, an allosteric inhibitor of prolactin action;. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc. ; Novartis Pharma AG; Novartis International Pharmaceutical Ltd. ; Rezolute, Inc.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.